Mutations or abnormal expression levels of specific genes in the RLR signaling pathway, such as MAVS, TBK1, and IRF3, can lead to changes in the immune signaling pathway, resulting in a decreased ability of immune cells to recognize and clear malignant tumors (Pecori et al., 2023). This evidence concerns the gene MAVS and cancer.